Date: 2014-09-02
Type of information: Fundraising
Company: Quantum Genomics (France)
Investors: Bpifrance (France)
Amount: 260 K€
Funding type: fundraising
Planned used: Financial aid from Bpifrance (France Public Innovation Bank) will support Quantum Genomics\' research program evaluating combinations of its new class of molecules (BAPAIs - Brain Aminopeptidase A Inhibitors) with other anti-hypertensive compounds. The synergistic actions expected from the effects of its lead product QGC001 and those of other anti-hypertensive agents may allow to reduce treatment doses and minimize side effects. More importantly, the association of QGC001 with other anti-hypertensives may become a therapeutic solution for the poorly or totally not controlled patients, who represent more than 50% of individuals treated by existing anti-hypertensive drugs. This research program with a 19 months duration (June 2014 to December 2015) is based on 2 modules: - Preclinical pharmacology studies in spontaneously hypertensive rats to assess the efficiency of QGC001 in combination with compounds representing four main classes of anti-hypertensive drugs: Diuretics, Calcium Channel Blockers, Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Antagonists (ARAs). - Regulatory preclinical studies aiming to demonstrate the bioavailability and safety of QGC011, a combination of QGC001 with Enalapril (ACE inhibitor), to supplement the promising results already obtained.
Others: * On September 2, 2014, Quantum Genomics, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces it received a 260 K€ subsidized financing from Bpifrance for its research program assessing combinations of BAPAIs (Brain Aminopeptidase A Inhibitors) with other anti-hypertensive compounds. The financial support provided by BPI France applies to a research program with a 19 months duration (June 2014 to December 2015). With this new public aid, the total amount of financings received from Bpifrance and ANR (National Research Agency) by Quantum Genomics since its inception is 1.8 M€.
Therapeutic area: Cardiovascular diseases
